title: Patient-reported and Cost-effectiveness Outcomes Are Key to Determining the Optimal Therapeutic Sequence for Patients with Metastatic Renal Cell Carcinoma.
authors.affiliation: Division of Urologic Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA.
authors.forename: Benjamin T
authors.initials: BT
authors.lastname: Ristau
authors.affiliation: Medical Oncology, Fox Chase Cancer Center, Temple Health, Philadelphia, PA, USA. Electronic address: daniel.geynisman@fccc.edu.
authors.forename: Daniel M
authors.initials: DM
authors.lastname: Geynisman
mesh_terms: D002292:Carcinoma, Renal Cell; D003362:Cost-Benefit Analysis; D006801:Humans; D007680:Kidney Neoplasms; D016609:Neoplasms, Second Primary; D019057:Quality-Adjusted Life Years